|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002395,
umls-concept:C0005516,
umls-concept:C0007806,
umls-concept:C0008425,
umls-concept:C0087111,
umls-concept:C0449258,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1521828,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-5-19
|
|
pubmed:abstractText |
The main objective of this study was to investigate possible predictors of response to cholinesterase inhibitor (ChEI) treatment, including pre-treatment progression rates and levels of the cerebrospinal fluid (CSF) biomarkers. A secondary objective was to evaluate whether treatment with ChEI changed progression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1099-1166
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2009 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
638-47
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19123199-Aged,
pubmed-meshheading:19123199-Aged, 80 and over,
pubmed-meshheading:19123199-Alzheimer Disease,
pubmed-meshheading:19123199-Amyloid beta-Peptides,
pubmed-meshheading:19123199-Apolipoprotein E4,
pubmed-meshheading:19123199-Biological Markers,
pubmed-meshheading:19123199-Cholinesterase Inhibitors,
pubmed-meshheading:19123199-Disease Progression,
pubmed-meshheading:19123199-Female,
pubmed-meshheading:19123199-Genotype,
pubmed-meshheading:19123199-Geriatric Assessment,
pubmed-meshheading:19123199-Humans,
pubmed-meshheading:19123199-Male,
pubmed-meshheading:19123199-Models, Statistical,
pubmed-meshheading:19123199-Peptide Fragments,
pubmed-meshheading:19123199-Predictive Value of Tests,
pubmed-meshheading:19123199-Prospective Studies,
pubmed-meshheading:19123199-Psychological Tests,
pubmed-meshheading:19123199-Severity of Illness Index,
pubmed-meshheading:19123199-Sweden,
pubmed-meshheading:19123199-Treatment Outcome,
pubmed-meshheading:19123199-tau Proteins
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
|
|
pubmed:affiliation |
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden. asa.k.wallin@skane.se
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
